Last week's data deluge describing the most comprehensive map to date of regulatory elements in the human genome gave scientists new insights into how DNA that does not code for proteins functions within the genome. And that new understanding may enable them to get more information out of older genomewide association studies (GWAS). Read More
The demise of Bristol-Myers Squibb Co.'s hepatitis C drug BMS-986094, which BMS discontinued development of after patients in its Phase IIb study experienced heart and kidney toxicity, stretched further than just the big pharma. The FDA put a partial clinical hold on Idenix Pharmaceuticals Inc.'s related nuc IDX184 and then slapped a hold on its next-generation nuc, IDX19368, as well. Read More
There is plenty of evidence to suggest that small and emerging biotechnology companies could significantly benefit from modifications to the existing SEC rules and regulations affecting their access to the capital markets. Read More
